At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 38 enrolled
Drug / intervention
RVT-101 35 mg +1 moredrug
Likely dose
RVT-101 35 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-blind, Randomized, Placebo-controlled Crossover Study Evaluating the Effect of RVT-101 on Gait and Balance in Subjects With Alzheimer's Disease, Dementia With Lewy Bodies, or Parkinson's Disease Dementia
In Brief
A Phase 2 clinical trial evaluating RVT-101 35 mg and Placebo for Alzheimer's Disease and 2 related conditions. Completed, enrolled 38 participants across 11 sites.
Detailed Summary
This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartOct 2016
Primary CompletionNov 2017
TodayJul 2026
First PostedSep 21, 2016
Enrollment StartOct 1, 2016
Primary CompletionNov 1, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.8 years ago
Interventions
RVT-101 35 mgdrug
RVT-101 once daily, oral, 35-mg tablets
Placebodrug
Placebo once daily, oral